Lifeward Ltd. · NASDAQ:LFWD
Lifeward — Investor Presentation (September 2026)
17 slides from Lifeward's investor presentation, September 2026
Slide 1: Platform to Restore Motion, Dignity, and Independence
NASDAQ: LFWD Platform to Restore Motion, Dignity, and Independence Transforming Rehabilitation. Changing Lives. Investor Presentation · September 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”) and the safe harbor p
Slide 3: A Leading Restorative Healthcare Platform
INVESTMENT THESIS A Leading Restorative Healthcare Platform Lifeward is a global innovator restoring motion, independence, and quality of life—through market-leading neurorehabilitation technology built on advanced robotics, AI, and one of the industry’s most established reimbursement infrastructure
Slide 4: Large and Growing Rehabilitation Markets
MARKET OPPORTUNITY Large and Growing Rehabilitation Markets ROBOTICS + AI + REIMBURSEMENT ARE ACCELERATING ADOPTION MILLIONS OF PATIENTS IN NEED $17B1 Lifeward is uniquely positioned to capture this Spinal Cord Injury Rehabilitation Equipment Market growth. Stroke Neuro-Rehab $27B by 2030 · 8% CAGR
Slide 5: The Opportunity
BY THE NUMBERS The Opportunity GROWING REACH REIMBURSEMENT MOAT IN PLACE 37+ 40+ 7000+ ~46% Top 3 10+ years Countries Distributors Units deployed of Medicare Advantage Medicare Advantage To build moat enrollees have coverage insurers in U.S., 16M lives access covered OPERATING FOUNDATION MULTIPLE GR
Slide 6: Growth Portfolio Set to Scale
PORTFOLIO STRATEGY Growth Portfolio Set to Scale One Platform with Multiple Device Development Programs CURRENT PORTFOLIO INTERNAL INNOVATION ACQUISITIONS PARTNERSHIP UPSIDE Oratech Pharmaceuticals Ltd. Multiple revenue engines Pipeline + owned IP Aggregation readiness acquired from Oramed (Dates re
Slide 7: 1st FDA-Cleared Powered Exoskeleton with Medicare Coverage
PRODUCT · REWALK 1st FDA-Cleared Powered Exoskeleton with Medicare Coverage LIFEWARD CREATED THE POWERED EXOSKELETON CATEGORY Clinical Evidence 76% 3.3 METs ambulated without assistance Metabolic equivalent of task (MET) ReWalk users together in the field — independence, side by side Miller et al. 2
Slide 8: The Problem ReWalk Solves
CLINICAL NEED · REWALK The Problem ReWalk Solves The Patient Why Current Options Fail What ReWalk Changes • Individuals with spinal cord injury and • Traditional orthotic devices require • 76% ambulated without physical assistance neurological conditions who cannot walk unsustainable metabolic effor
Slide 9: NASA Anti-Gravity Rehabilitation
PRODUCT · ALTERG NASA Anti-Gravity Rehabilitation Technology • NASA-derived Differential Air Pressure (DAP) technology reduces the effects of gravity to enable users to move with calibrated support and reduced pain. • The only system that accurately assesses and calibrates body weight up to 100x/sec
Slide 10: Upper-Extremity Rehabilitation Platform Extension
PRODUCT · UPPER-EXTREMITY REHABILITATION Upper-Extremity Rehabilitation Platform Extension Product Capability Reimbursement Pathway Multi-joint powered arm with CMS L8702 established for upper- 1 individual finger control in 2 extremity orthotic at ~$60–65K development. AI intent recognition; rate.
Slide 11: Distribution: Far-Reaching Access Where Patients Need It Most
GO-TO-MARKET Distribution: Far-Reaching Access Where Patients Need It Most Working with the largest home medical equipment (HME) / durable medical equipment (DME) providers in the U.S. LIFEWARD CHANNEL PARTNERS PATIENTS IN COMMUNITY Designs · manufactures · supports HME/DME · billing · claims Care w
Slide 12: Reimbursement Moat: Code + Coverage + Payment
REIMBURSEMENT Reimbursement Moat: Code + Coverage + Payment A decade in the making; structurally defensible CODE COVERAGE PAYMENT K1007 ~46% $95,081 HCPCS code (2020) of MA enrollees established rate Billing infrastructure established Brace Benefit (2024) · MA approvals Medicare Fee Schedule (2026)
Slide 13: Pipeline & Connected Data Platform
Devices Under Development Pipeline & Connected Data Platform Each device under development runs on the same infrastructure, and each addition has the potential to compound the platform’s value (Anticipated launch dates subject to FDA clearance) 2027 2028 Early 2029 2030–31 AlterG StrideSense Upper-B
Slide 14: Financial Position and Strategic Partnership
FINANCIALS & PARTNERSHIP Financial Position and Strategic Partnership Operating metrics show commercialization underway; Oramed partnership funds execution Financial metrics as of June 30, 2026: $6.6M 42% $10.9M OpEx Operating expense trending Q2 revenue up 15% YoY Gross margin Pro forma cash positi
Slide 15: Oramed POD: Significant Upside Potential
POTENTIAL TRANSFORMATIVE VALUE Oramed POD : Significant Upside Potential Pre-funded · Exponential upside · Phase 2B for lead asset ORMD-0801 in development WHAT POD REPRESENTS TRIAL HISTORY AND FORWARD PATH TRANSFORMATIONAL VALUE • Oramed’s oral protein delivery platform: • Phase 3 US trial did not
Slide 16: Why Now
INVESTMENT SUMMARY Why Now Coverage exists. Infrastructure is built. Robotics & AI transforming rehabilitation market Expanding distribution channels 1 2 Lifeward is an early leader, with infrastructure built, in a $17B rehab Increasing patient access, accelerating commercial expansion and equipment
Slide 17: Thank You
NASDAQ: LFWD Thank You Restoring motion, dignity, and independence for the people whose lives depend on it. We welcome your questions and discussion. Investor Presentation · September 2026